TNFRSF9 and prostate carcinoma: In publicly available data for previously treated patients, high expression of TNFRSF9 and LRP1 significantly correlated with a shorter progression free survival in patients with prostate cancer; HOMER1 was not statistically significant (p-value = 0.183) (Fig. 6C).